胆酶抑制剂与心力衰竭的较低死亡率相关:多中心倾向评分研究
Ming-Jer Hsieh1, Cheng-Hung Lee2, Dong-Yi Chen2
1Division of Cardiology, Department of Internal Medicine, Chang Gung Memorial Hospital, Linkou, Taiwan; College of Medicine, Chang Gung University, Taoyuan, Taiwan; Heart failure center, Chang Gung Memorial Hospital, Linkou, Taiwan.
The Canadian journal of cardiology
|August 21, 2025
概括
胆酶抑制剂显著降低了心力衰竭患者的死亡率和心力衰竭患者的住院治疗 (HFpEF). 这表明ChEIs可能是HFpEF的可行治疗方法.
科学领域:
- 心脏病学
- 药理学
- 医学研究
背景情况:
- 通过阴道调节的副交感途径是心力衰竭 (HF) 的未充分研究的治疗策略.
- 胆酶抑制剂 (ChEIs) 增强胆基调,并且在HF患者中显示出治疗效益.
- 本研究检查了CHEI使用对诊断为心力衰竭与保存喷射分数 (HFpEF) 的患者的临床结果的影响.
研究的目的:
- 研究使用胆酶抑制剂 (ChEIs) 与心力衰竭患者 (HFpEF) 的临床结果之间的关联.
主要方法:
- 一项回顾性队列研究利用了2002年7月至2022年12月的多机构数据库.
- HFpEF被定义为左心室喷射分数> 50% 和H2FPEF得分≥6.
- 首要终点包括全因和心血管死亡率,以及在5年的随访期内住院治疗HF.
主要成果:
- 使用CHEI与显著降低全因死亡率 (HR 0.45) 和心血管死亡率 (HR 0.41) 有关.
- 与非使用者相比,使用ChEIs的患者心力衰竭住院的次数较少 (HR0. 52).
- 对于使用CHEI的患者,左心室填充压的发生率较低 (E/ e≥13) (43. 4%对65. 1%,p=0. 010).
结论:
- 在HFpEF中,胆酶抑制剂治疗与死亡率和HF住院率的显著降低有关.
- 在ChEI使用者中观察到左心室填充压力的改善.
- 这些发现需要进行进一步的前性试验,以评估CHEIs作为HFpEF的潜在治疗选择.
相关概念视频
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:30Indirect-Acting Cholinergic Agonists: Pharmacological Actions
828
Indirect-acting cholinergic agonists, also known as anticholinesterases, exert their pharmacological effects by enhancing cholinergic transmission in various body parts, including the neuromuscular junction, autonomic cholinergic synapses, and the brain.
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
At the neuromuscular junction, these agents work by inhibiting the breakdown of acetylcholine, allowing it to remain bound to the receptor and bind to nearby receptors. This process leads to repetitive firing of the endplate, causing muscle...
828
01:26Anticholinesterase Agents: Poisoning and Treatment
1.0K
Anticholinesterases, also known as cholinesterase inhibitors, work by blocking the breakdown of acetylcholine, leading to its accumulation in the synaptic cleft. This accumulation indirectly enhances both muscarinic and nicotinic actions. These agents are classified as reversible or irreversible based on their mechanism of action.
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
Irreversible agents form a strong bond with the cholinesterase enzyme, making it inactive. The breakdown of the phosphorylated enzyme is...
1.0K
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
2.0K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
2.0K
01:22Heart Failure Drugs: β-Blockers
434
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
434